Hims & Hers Stock Surges 48% In One Week Thanks to RFK Jr.’s Peptide Push
Topline
Hims & Hers Health inventory climbed as a lot as 11% Monday, persevering with a week-long rally after the FDA introduced a gathering to talk about easing peptide regulation—a push repeatedly championed by Robert F. Kennedy Jr.
(Photo by Alex Wong/Getty Images)
Getty Images
Key Facts
Hims & Hers inventory is up as a lot as 11% as we speak and has emerged greater than 125% since its lows in February, when the inventory was experiencing a chronic downturn that began late 2025.
Last week, the inventory started rallying after the FDA introduced it could maintain a gathering in July to take into account easing regulation round peptides—the overarching class of medicine that not solely embody the well-known and controlled GLP-1s, but in addition numerous gray-market injectables which have exploded in recognition on social media on guarantees of outcomes like higher pores and skin, sooner therapeutic and slower growing old.
On April 15, Health Secretary Robert F. Kennedy Jr. introduced the FDA—which restricted 19 peptides in 2023 citing well being dangers—will consider eradicating 12 peptides from its restrictions, doubtlessly clearing a regulatory path for telehealth platforms together with Hims to supply peptide therapies.
RFK Jr. has lengthy been a loud proponent of peptides, claiming on Joe Rogan’s podcast in February that he has personally benefited from utilizing peptides.
Hims acquired a California-based peptide manufacturing facility in February 2025, positioning the corporate to produce peptide therapies at scale ought to regulate green-light the class.
Key Background
Hims & Hers constructed its enterprise on direct-to-consumer prescriptions for well being circumstances together with hair loss, erectile dysfunction, psychological well being and skincare, however its breakout progress got here from promoting compounded variations of GLP-1 weight-loss medication throughout the shortages of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound round 2024. That technique fueled a 59% income enhance in 2025 to $2.35 billion however uncovered the corporate to vital regulatory and authorized danger. An preliminary April 2025 partnership between Hims and Novo Nordisk collapsed inside two months after Novo accused the telehealth firm of “deceptive promotion” of “knockoff” Wegovy variations—setting off almost a yr of litigation, FDA warning letters and public feuding. In March, Hims and Novo Nordisk entered an settlement for Hims to prioritize distributing Novo’s branded GLP-1s in trade for Novo to drop the lawsuit. With Hims’ extremely worthwhile GLP-1 product changed with branded variations—and administration guiding softer 19% income progress this yr—the corporate is pivoting to new avenues to herald related revenue margins as the load loss drug. The firm confirmed in its February earnings name that it’s creating a peptide-based product line as a part of a long life specialty deliberate to launch this yr.
Big Number
$500 billion. That’s how a lot market cap Novo Nordisk has misplaced from its peak in 2024. Once Europe’s most dear firm, the GLP-1 maker has confronted rising competitors from American competitor Eli Lilly and compounding pharmacies like Hims that compelled it to reduce costs dramatically to keep market share.
Tangent
Peptides have develop into one of many buzziest wellness developments on the web as we speak. Compounds like BPC-157, GHK-Cu and numerous GLP analogs have proliferated longevity throughout clinics, influencer advertising channels and gray-market retailers over the previous three years, regularly offered with claims about tissue restore, fats loss, pores and skin well being and “organic age reversal.” Much of that market operated in a regulatory limbo—not fairly prescription drug, not fairly complement—till the FDA’s 2023 restrictions formalized which peptides may and could not be produced by compounding pharmacies like Hims. The restrictions have led to the surging recognition of peptides imported from abroad, with “Chinese peptides” changing into a biohacking fad amongst Silicon Valley’s younger tech staff, in accordance to the New York Times. These unregulated compounds have additionally been reaching more and more younger audiences as “looksmaxxers”—younger males on social media who interact in excessive measures to maximize their bodily look—have notoriously used and promoted them.
